Mucoadhesive gellan gum-based and carboxymethyl cellulose-based hydrogels containing gemcitabine and papain for bladder cancer treatment

Author(s)

de Lima, Caroline S. A. ; Rial-Hermida, M. Isabel ; de Freitas, Lucas Freitas ; Pereira-da-Mota, Ana F. ; Vivero-Lopez, Maria ; Ferreira, Aryel Heitor ; Kadlubowski, Slawomir ; Varca, Gustavo H. C. ; Lugao, Ademar B. ; Alvarez-Lorenzo, Carmen

• Document type: Journal article
• Source: International Journal of Biological Macromolecules; v. 242, p. 16-pg., 2023-05-24.

Abstract

Local treatment of bladder cancer faces several limitations such as short residence time or low permeation through urothelium tissue. The aim of this work was to develop patient-friendly mucoadhesive gel formulations combining gemcitabine and the enzyme papain for improved intravesical chemotherapy delivery. Hydrogels based on two different polysaccharides, gellan gum and sodium carboxymethylcellulose (CMC), were prepared with either native papain or papain nanoparticles (nanopapain) to explore for the first time their use as permeability enhancers through bladder tissue. Gel formulations were characterized regarding enzyme stability, rheological behavior, retention on bladder tissue and bioadhesion, drug release properties, permeation capacity, and biocompatibility. After 90 days of storage, the enzyme loaded in the CMC gels retained up to 83.5 & PLUSMN; 4.9 % of its activity in the absence of the drug, and up to 78.1 & PLUSMN; 5.3 with gemcitabine. The gels were mucoadhesive and the enzyme papain showed mucolytic action, which resulted in resistance against washing off from the uro-thelium and enhanced permeability of gemcitabine in the ex vivo tissue diffusion tests. Native papain shortened lag-time tissue penetration to 0.6 h and enhanced 2-fold drug permeability All formulations demonstrated pseudoplastic behavior and no irritability. Overall, the developed formulations have potential as an upgraded alternative to intravesical therapy for bladder cancer treatment. (AU)

• FAPESP's process: 17/50332-0 - Scientific, technological and infrastructure qualification in radiopharmaceuticals, radiation and entrepreneurship for health purposes (PDIp)
• Grantee: Marcelo Linardi
• Support Opportunities: Research Grants - State Research Institutes Modernization Program